Gelteq's Gel-Based Tech Validated in Animal Trials, Boosting Partnership Prospects
GELS has more than doubled off its 52-week low of $0.387 on elevated volume (1.9× avg).
Summary
Gelteq successfully completed veterinary palatability trials with Kemin, validating its proprietary gel-based drug delivery technology for animal health applications. The trials demonstrated strong canine acceptance and the ability to effectively mask bitter flavors, a critical factor for successful animal therapeutics. This positive outcome strengthens Gelteq's market position and is expected to accelerate discussions with potential strategic partners. This development follows recent news of the company securing debt financing and commencing its first clinical trial for an antiparasitic drug, highlighting ongoing progress in its pipeline.
At the time of this announcement, GELS was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.39 to $2.63. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.